188 related articles for article (PubMed ID: 19128367)
1. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
Herring N; Szmigielski C; Becher H; Karavitaki N; Wass JA
Clin Endocrinol (Oxf); 2009 Jan; 70(1):104-8. PubMed ID: 19128367
[TBL] [Abstract][Full Text] [Related]
2. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
Halperin I; Aller J; Varela C; Mora M; Abad A; Doltra A; Santos AE; Batista E; García-Pavía P; Sitges M; Mirelis JG; Lucas T; Puig-Domingo M
Clin Endocrinol (Oxf); 2012 Aug; 77(2):275-80. PubMed ID: 22288503
[TBL] [Abstract][Full Text] [Related]
3. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
4. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
Kars M; Pereira AM; Bax JJ; Romijn JA
Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
[TBL] [Abstract][Full Text] [Related]
7. [Cabergoline in hyperprolactinemia and valvular heart disease].
Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
[TBL] [Abstract][Full Text] [Related]
8. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.
Delgado V; Biermasz NR; van Thiel SW; Ewe SH; Marsan NA; Holman ER; Feelders RA; Smit JW; Bax JJ; Pereira AM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):99-105. PubMed ID: 22211510
[TBL] [Abstract][Full Text] [Related]
9. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
Boguszewski CL; dos Santos CM; Sakamoto KS; Marini LC; de Souza AM; Azevedo M
Pituitary; 2012 Mar; 15(1):44-9. PubMed ID: 21847572
[TBL] [Abstract][Full Text] [Related]
10. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.
Vallette S; Serri K; Rivera J; Santagata P; Delorme S; Garfield N; Kahtani N; Beauregard H; Aris-Jilwan N; Houde G; Serri O
Pituitary; 2009; 12(3):153-7. PubMed ID: 18594989
[TBL] [Abstract][Full Text] [Related]
11. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
Colao A; Galderisi M; Di Sarno A; Pardo M; Gaccione M; D'Andrea M; Guerra E; Pivonello R; Lerro G; Lombardi G
J Clin Endocrinol Metab; 2008 Oct; 93(10):3777-84. PubMed ID: 18682513
[TBL] [Abstract][Full Text] [Related]
12. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Nachtigall LB; Valassi E; Lo J; McCarty D; Passeri J; Biller BM; Miller KK; Utz A; Grinspoon S; Lawson EA; Klibanski A
Clin Endocrinol (Oxf); 2010 Jan; 72(1):53-8. PubMed ID: 19508591
[TBL] [Abstract][Full Text] [Related]
13. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
[TBL] [Abstract][Full Text] [Related]
14. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
15. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
16. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
Tan T; Cabrita IZ; Hensman D; Grogono J; Dhillo WS; Baynes KC; Eliahoo J; Meeran K; Robinson S; Nihoyannopoulos P; Martin NM
Clin Endocrinol (Oxf); 2010 Sep; 73(3):369-74. PubMed ID: 20550538
[TBL] [Abstract][Full Text] [Related]
17. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
[TBL] [Abstract][Full Text] [Related]
18. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study.
Ozer N; Yorgun H; Canpolat U; Elibol B
Anadolu Kardiyol Derg; 2014 Mar; 14(2):121-7. PubMed ID: 24449623
[TBL] [Abstract][Full Text] [Related]
20. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?
Gu H; Luck S; Carroll PV; Powrie J; Chambers J
Clin Endocrinol (Oxf); 2011 May; 74(5):608-10. PubMed ID: 21198745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]